PROCEEDINGS VOLUME 2371
FIFTH INTERNATIONAL PHOTODYNAMIC ASSOCIATION BIENNIAL MEETING | 21-24 SEPTEMBER 1994
5th International Photodynamic Association Biennial Meeting
FIFTH INTERNATIONAL PHOTODYNAMIC ASSOCIATION BIENNIAL MEETING
21-24 September 1994
Amelia Island, FL, United States
State of the Art: Technology
Proc. SPIE 2371, Clinically relevant technology in photodynamic therapy and photodynamic diagnosis, 0000 (1 March 1995); doi: 10.1117/12.203352
Photosensitizers I
Proc. SPIE 2371, Photodynamic therapy using 5-aminolevulinic acid-induced photosensitization: current clinical status, 0000 (1 March 1995); doi: 10.1117/12.203429
Proc. SPIE 2371, Studies on 5,10,15,20-tetrakis(m-hydroxyphenyl)chlorin, mTHPC (Temoporfin), 0000 (1 March 1995); doi: 10.1117/12.203441
Mechanisms of PDT I
Proc. SPIE 2371, Influence of serum proteins on the accumulation of aminolaevulinic acid-induced protoporphyrin IX in cells in culture, 0000 (1 March 1995); doi: 10.1117/12.203356
Proc. SPIE 2371, Comparison of the influence of a water-soluble polymer carrier on the tumor localization and biodistribution of mesotetrametahydroxyphenylchlorin (mTHPC) in two animal models, 0000 (1 March 1995); doi: 10.1117/12.203361
Proc. SPIE 2371, Evaluation with mTHPC of early squamous cell carcinomas of the cheek pouch mucosa of Golden Syrian hamsters as a model for clinical PDT of early cancers in the upper aerodigestive tract, the esophag, 0000 (1 March 1995); doi: 10.1117/12.203366
Proc. SPIE 2371, Photodynamic effect on specific antitumor immune activity, 0000 (1 March 1995); doi: 10.1117/12.203377
Tissue Fluorescence I
Proc. SPIE 2371, Fluorescence spectroscopy for colon cancer diagnosis, 0000 (1 March 1995); doi: 10.1117/12.203411
Clinical I
Proc. SPIE 2371, Fluorescence tissue distribution of methylene blue used for photodynamic therapy of Helicobacter Pylori, 0000 (1 March 1995); doi: 10.1117/12.203417
Proc. SPIE 2371, Photodynamic therapy in early esophageal squamous cell carcinoma, 0000 (1 March 1995); doi: 10.1117/12.203428
Photosensitizers II
Proc. SPIE 2371, Effectiveness of photodynamic therapy with a diode laser using mono-L-aspartyl chlorin e6 for implanted fibrosarcoma in mice, 0000 (1 March 1995); doi: 10.1117/12.203430
Mechanisms of PDT II
Proc. SPIE 2371, Cell death mechanisms vary with photodynamic therapy dose and photosensitizer, 0000 (1 March 1995); doi: 10.1117/12.203431
Proc. SPIE 2371, Intracellular uptake kinetics of hypocrellin photosensitizers for photodynamic therapy, 0000 (1 March 1995); doi: 10.1117/12.203432
Tissue Fluorescence II
Proc. SPIE 2371, In vivo monitoring of photosensitizer fluorescence during photodynamic therapy, 0000 (1 March 1995); doi: 10.1117/12.203433
Proc. SPIE 2371, Fluorescence imaging photodetection of early cancer in the bronchi with mTHPC and in the bladder with ALA-induced protoporphyrin IX: preliminary clinical results, 0000 (1 March 1995); doi: 10.1117/12.203434
Proc. SPIE 2371, In vivo fluorescence imaging of lysosomes: a potential technique to follow dye accumulation in the context of PDT?, 0000 (1 March 1995); doi: 10.1117/12.203435
Proc. SPIE 2371, Enhanced photodynamic therapy and dosimetry by light-induced fluorescence, 0000 (1 March 1995); doi: 10.1117/12.203436
Clinical II
Proc. SPIE 2371, Clinical and experimental results of photodynamic therapy in neurosurgery, 0000 (1 March 1995); doi: 10.1117/12.203437
Proc. SPIE 2371, Fluorescence diagnostics of head and neck cancer utilizing oral administration of delta-amino levulinic acid, 0000 (1 March 1995); doi: 10.1117/12.203438
Photosensitizers III
Proc. SPIE 2371, Response of U-87MG in nude rats in photodynamic therapy, 0000 (1 March 1995); doi: 10.1117/12.203439
Mechanisms of PDT III
Proc. SPIE 2371, Light distribution and optical coefficients in prostate tumor, 0000 (1 March 1995); doi: 10.1117/12.203440
Tissue Fluorescence III
Proc. SPIE 2371, Tumor-localizing fluorescent diagnostic agents without phototoxicity: HAT-D01, 0000 (1 March 1995); doi: 10.1117/12.203442
Proc. SPIE 2371, Measurement of the photodynamic dose in an optical phantom, 0000 (1 March 1995); doi: 10.1117/12.203443
Clinical III
Proc. SPIE 2371, Photodynamic therapy of malignant mesothelioma of pleura, 0000 (1 March 1995); doi: 10.1117/12.203444
Photosensitizers IV
Proc. SPIE 2371, In vivo and in vitro absorption spectrum of disulphonated aluminum phthalocyanine in tumor-bearing mice, 0000 (1 March 1995); doi: 10.1117/12.203445
Mechanisms of PDT IV
Proc. SPIE 2371, Significance of threshold doses for photodynamic therapy of melanotic and amelanotic tumors, 0000 (1 March 1995); doi: 10.1117/12.203446
Proc. SPIE 2371, Tissue distribution of liposomal zinc(II)-phthalocyanine in normolipaemic and hyperlipaemic rats following intravenous administration, 0000 (1 March 1995); doi: 10.1117/12.203447
Proc. SPIE 2371, Localization of zinc(II)-phthalocyanine within implanted tumors after intravenous administration of a liposomal formulation, 0000 (1 March 1995); doi: 10.1117/12.203448
Proc. SPIE 2371, Photodynamic response of an endothelial hybridoma cell line using zinc(II) tetrasubstituted phthalocyanines, 0000 (1 March 1995); doi: 10.1117/12.203449
Mechanisms of PDT V
Proc. SPIE 2371, Chemical instability of 5-aminolevulinic acid (ALA) in aqueous solution, 0000 (1 March 1995); doi: 10.1117/12.203450
Proc. SPIE 2371, Increased vascular permeability of solid tumors causes selectivity of 5-aminolevulinic acid (ALA) induced porphyrins, 0000 (1 March 1995); doi: 10.1117/12.203451
Proc. SPIE 2371, Exogenous delta-animolevulinic acid induces the porphyrin biosynthesis in human skin organ cultures with different porphyrin patterns in normal and malignant human tissue, 0000 (1 March 1995); doi: 10.1117/12.203452
Clinical IV
Proc. SPIE 2371, Topical photodynamic therapy with 5-ALA in the treatment of arsenic-induced skin tumors, 0000 (1 March 1995); doi: 10.1117/12.203453
Proc. SPIE 2371, Photodynamic therapy with 5-aminoolevulinic acid-induced porphyrins and DMSO/EDTA for basal cell carcinoma, 0000 (1 March 1995); doi: 10.1117/12.203454
Proc. SPIE 2371, Photodynamic therapy with aminolevulinic acid and meso-tetrahydroxyphenylchlorin: first initial clinical experience in Egypt, 0000 (1 March 1995); doi: 10.1117/12.203455
Proc. SPIE 2371, Photodynamic therapy of nonmelanoma skin malignancies with topical delta-amino levulinic acid: diagnostic measurements, 0000 (1 March 1995); doi: 10.1117/12.203456
Clinical V
Proc. SPIE 2371, Photodynamic therapy using 5-aminolaevulinic acid in oral malignancy and premalignancy, 0000 (1 March 1995); doi: 10.1117/12.203457
Proc. SPIE 2371, Meta-tetrahydroxyphenylchlorin (mTHPC) mediated photodynamic therapy: experience and thoughts after 17 treatments, 0000 (1 March 1995); doi: 10.1117/12.203353
Photosensitizers V
Proc. SPIE 2371, Detection of singlet oxygen yield from new photosensitizers using luminol, 0000 (1 March 1995); doi: 10.1117/12.203354
Proc. SPIE 2371, Distribution and photodynamic effect of meta-tetrahydroxyphenylchlorin (mTHPC) in the pancreas and adjacent tissues in Syrian golden hamsters, 0000 (1 March 1995); doi: 10.1117/12.203355
Mechanisms of PDT VI
Proc. SPIE 2371, Model of the haem biosynthetic pathway, 0000 (1 March 1995); doi: 10.1117/12.203357
Proc. SPIE 2371, HepG2 human hepatocarcinomas cells sensitization by endogenous porphyrins, 0000 (1 March 1995); doi: 10.1117/12.203358
Proc. SPIE 2371, Urothelial conversion of 5-aminolevulinic acid to protoporphyrin IX following oral or intravesical administration, 0000 (1 March 1995); doi: 10.1117/12.203359
Proc. SPIE 2371, Biodistribution and photodynamic effect of protoporphyrin IX in rat urinary bladders after intravesical instillation of 5-aminolaevulinic acid, 0000 (1 March 1995); doi: 10.1117/12.203360
Mechanisms of PDT VII
Proc. SPIE 2371, Tumor responses after combined PDT and hyperthermia, 0000 (1 March 1995); doi: 10.1117/12.203362
Clinical VI
Proc. SPIE 2371, Is photodynamic therapy a selective treatment? Analysis of local complications after endoscopic photodynamic therapy of early stage tumors of gastrointestinal, tracheobronchial, and urinary tracts, 0000 (1 March 1995); doi: 10.1117/12.203363
Proc. SPIE 2371, 7, 12 dimethylbenz(a)anthracene(DMBA)-induced "early" Squamous Cell carcinoma in the Golden Syrian hamster: evaluation of an animal model and comparison with "early" forms of human Squamous Cell car, 0000 (1 March 1995); doi: 10.1117/12.203364
Clinical VII
Proc. SPIE 2371, Effect of tin etiopurpurin and light on the canine prostate, 0000 (1 March 1995); doi: 10.1117/12.203365
Proc. SPIE 2371, Removal of the intestinal mucosa: photochemical approach in bladder augmentation, 0000 (1 March 1995); doi: 10.1117/12.203367
Photosensitizers VI
Proc. SPIE 2371, Application of 1,2-diethyl-3-hydroxypyridin-4-one to enhance tissue selectivity for photodynamic therapy of the bladder, 0000 (1 March 1995); doi: 10.1117/12.203368
Proc. SPIE 2371, New cancer-treatment model of photodynamic therapy combined with a type I topoisomerase inhibitor, CPT-11, against HeLa cell tumors in nude mice used by OPO parametric tunable laser, 0000 (1 March 1995); doi: 10.1117/12.203369
Mechanisms of PDT VIII
Proc. SPIE 2371, Photodynamic therapy with cationic photosensitizers, 0000 (1 March 1995); doi: 10.1117/12.203370
Proc. SPIE 2371, Serum levels of hematoporphyrin derivatives in the photodynamic therapy of malignant tumors, 0000 (1 March 1995); doi: 10.1117/12.203371
Proc. SPIE 2371, Tumor-associated macrophages (not tumor cells) are the determinants of photosensitizer tumor localization, 0000 (1 March 1995); doi: 10.1117/12.203372
Proc. SPIE 2371, Potentiation of photodynamic therapy by granulocyte-macrophage colony stimulating factor immunotherapy, 0000 (1 March 1995); doi: 10.1117/12.203373
Proc. SPIE 2371, Mechanism of photodynamic therapy (PDT): investigation of sensitizer dose and light dose-rate effects, 0000 (1 March 1995); doi: 10.1117/12.203374